Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management—An Insight into Future Approaches

Table 2

Details of clinical studies investigating efficacy of long-term treatment with LMWH in resistant thrombotic APS.

Author, year [Ref]	Type of study	patients	Inclusion criteria	Treatments	Observation time	Recurrence Rate
Bick and Rice, 1999 [45]	Retrospective	24	APS patients resistant or intolerant to warfarin	Dalteparin	309 days	0
Ahmed et al., 2002 [46]	Case-report	1	APS patient with difficulties in keeping INR in target	Enoxaparin 1.5 mg/kg daily	90 days	1 (pulmonary TE)
Dentali et al., 2005 [47]	Case-report	2	APS patients refractory to warfarin	Enoxaparin 10000 IU td; Dalteparin 10000 U td	2 years; 6 years	0
Vargas-Hitos et al., 2011 [48]	Retrospective	23	APS patients refractory to warfarin	Enoxaparin	36 months	0.13